Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Vasco Videira Dias"'
Autor:
Sofia Brissos, Vasco Videira Dias, Márcio Gerhardt Soeiro-de-Souza, Vicent Balanzá-Martínez, Flavio Kapczinski
Publikováno v:
Brazilian Journal of Psychiatry, Vol 33, Iss 4, Pp 353-361 (2011)
BACKGROUND: About two-thirds of patients with bipolar disorder (BD) have a lifetime history of at least one psychotic symptom. Objective: To compare the neurocognitive performance of four groups: BD patients with and without a history of psychotic sy
Externí odkaz:
https://doaj.org/article/fcd896ba19404dafa6acfd72b161f5e0
Publikováno v:
Acta Médica Portuguesa, Vol 21, Iss 6 (2009)
Bipolar disorder (BD) is a chronic mental disorder that affects 1-3% of the population, and is characterized by affective episodes that alternate with periods of euthymia. Although traditionally patients were thought to return to premorbid functionin
Externí odkaz:
https://doaj.org/article/90c91594c27140fd833556afd4a8b018
Publikováno v:
Clinical Management of Bipolar Disorder. :78-86
Autor:
Ana Ferro, Isabel do Carmo, R. Duarte, António Barbosa, Carlos Góis, Filomena Sousa, Vasco Videira Dias, Andreia Santos
Publikováno v:
Clinical Psychology & Psychotherapy. 21:39-48
Aims: Major depression is more prevalent in patients with type 2 diabetes mellitus (T2DM) than in general population. Comparing psychotherapeutic and pharmacological treatment responses could help to inform the choice between available treatment opti
Autor:
K. de Barros Pellegrinelli, Vasco Videira Dias, F. Colom, Mireia C Roso, L. F. de O. Costa, Marina Bandeira, Ricardo Alberto Moreno, K. I. D. Silval
Publikováno v:
Acta Psychiatrica Scandinavica. 127:153-158
Objective: To evaluate the efficacy of psychoeducation in the symptomatic and functional recovery, and quality of life (QoL) in a sample of patients with bipolar disorder (BD). Method: The sample comprised 55 patients with BD I and II in remission (Y
Autor:
Vasco Videira Dias, Maria Luísa Figueira, Vicent Balanzá-Martínez, Márcio Gerhardt Soeiro-de-Souza, Eduard Vieta, Ricardo Alberto Moreno, Rodrigo Machado-Vieira
Publikováno v:
Acta Psychiatrica Scandinavica. 126:315-331
Dias VV, Balanza-Martinez V, Soeiro-de-Souza MG, Moreno RA, Figueira ML, Machado-Vieira R, Vieta E. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Objective: Historically, pharmacological treatments
Autor:
Maria Luísa Figueira, Orestes Vicente Forlenza, Wagner F. Gattaz, Rodrigo Machado-Vieira, Vasco Videira Dias, Márcio Gerhardt Soeiro-de-Souza, Carlos A. Zarate
Publikováno v:
Acta Psychiatrica Scandinavica. 126:332-341
Objective Bipolar disorder (BD) likely involves, at a molecular and cellular level, dysfunctions of critical neurotrophic, cellular plasticity and resilience pathways and neuroprotective processes. Therapeutic properties of mood stabilizers are presu
Autor:
Sofia Brissos, Vicent Balanzá-Martínez, Ana Isabel Carita, Vasco Videira Dias, Maria Luísa Figueira
Publikováno v:
European Archives of Psychiatry and Clinical Neuroscience. 261:509-517
Subjective quality of life (QoL) and psychosocial functioning constitute important treatment outcomes in schizophrenia. We aimed to investigate the relationship between them in schizophrenia patients living in the community. Symptom severity and insi
Autor:
Elida B. Ojopi, Luis Felipe de Oliveira Costa, Doris Hupfeld Moreno, Ricardo Alberto Moreno, Vasco Videira Dias, Carolina Martins do Prado, Wagner F. Gattaz, Rodolfo Nunes Campos, Danielle Soares Bio, Márcio Gerhardt Soeiro de Souza
Publikováno v:
CNS Neuroscience & Therapeutics. 16:316-321
Apolipoprotein E (APOE) has been extensively studied as a risk factor for sporadic and late onset Alzheimer's Disease (AD). APOE allele (∗)3, the most frequent variant, is not associated to cognitive dysfunction (CD) or to increased AD risk. Differ
Autor:
Flávio Kapczinski, Elisa Brietzke, Vasco Videira Dias, Gustavo H. Vázquez, Eduard Vieta, Michael Berk, Márcia Kauer-Sant'Anna
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 33:1366-1371
Recent data show that biomarkers differ in early and late-stage bipolar disorder (BD). Here we propose a model of staging for bipolar disorder that emphasizes the potential use of biomarkers for differentiating early and late-stage BD patients in the